Navigation Links
Skin & Aging Article Finds Derma Sciences MEDIHONEY(TM) Helps to Promote Healing Where Antibiotics Fail

Researchers Work in-vitro on MRSA, VRE and other multi-resistant organisms

PRINCETON, N.J., May 2 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, today announced that the journal Skin & Aging, in its annual review of top wound care studies, devoted a section to MEDIHONEY(TM) Wound & Burn Dressings with Active Leptospermum Honey. The article, "Spotlighting the Top-10 Research Findings in Wound Care", discusses the research done by Narelle George and Keith Cutting on the product's in-vitro activity against clinical isolates of MRSA, VRE, and other multi-resistant gram-negative organisms including Pseudomonas aeruginosa.

The author of the article, Dr. Robert Kirsner, MD, PhD, and a past president of the Association for the Advancement of Wound Care, states, "A specific honey, the so-called Manuka honey predominantly sourced from the Leptospermum species from New Zealand and Australia, has been found to have other properties that may render it superior to other honeys. Specifically, this honey appears to have superior and broad-spectrum antimicrobial properties." He went on to say that the first Leptospermum honey-based product to enter into the market, MEDIHONEY, is likely to draw significant interest from a public desirous of natural products, and that well-done studies such as the George/Cutting study will help to garner interest by medical professionals.

Derma Sciences CEO Ed Quilty stated, "We are fully aware that, although the benefits of MEDIHONEY have captured the imagination of the public and the medical community alike, it is only through well-designed studies and rigorous clinical evaluations with positive outcomes that widespread adoption and usage of MEDIHONEY will occur. We are glad to see the recognition of the George/Cutting study, and look forward to additional studies on MEDIHONEY being published later this year. Additionally, we continue to receive a stream of positive clinical evaluations from many wound centers around the globe."

Quilty added, "Our next big milestone is the World Union of Wound Healing Societies conference in Toronto during the first week in June. This conference takes place only once every four years and it draws doctors interested in wound care from all over the globe."
The Skin & Aging article also makes several additional key points:

-- A retrospective study of 400 patients with wounds (pressure ulcers,

diabetic ulcers, and venous ulcers) showed that wounds treated more

frequently with antimicrobial dressings appeared less likely to heal

rapidly, as did ulcers that that were mechanically debrided.

-- A randomized controlled study on healing rates of 71 non-healing venous

leg ulcers showed that none of the patients receiving conservative care

-- defined as the use of hydrocolloid dressings under compression

devices -- saw the ulcers heal completely during the duration of the

6-month study period. Hydrocolloids are one of the most typical

advanced wound care dressings utilized for first-line treatment of


Both these points are notable with comparison to the recent Georgina Gethin study presented last Spring at the European Wound Management Association. This 108-patient randomized controlled study showed that 44% of the non-healing venous leg ulcers treated with Active Leptospermum Honey under compression devices healed within the 12-week study duration, in addition to lowering the incidence of infection. This underscores the wound healing benefit of the dressing in addition to its antimicrobial capability, a feature atypical within common antimicrobial dressings. The study also showed that the dressing was associated with improved autolytic debridement (a more natural and less invasive form of debridement than surgical/mechanical debridement).

To read the article, please go to:

(Information in this article concerns a use that has not been cleared by the US Food and Drug Administration.)

About Skin & Aging

Skin & Aging provides practical and clinical insight into today's general dermatology issues. This award-winning publication offers dermatologists reader-friendly, timely and informative articles that highlight clinical and practice management advice that easily can be translated into current practice settings.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of two positive large-scale randomized controlled studies on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.

Contact: Derma Sciences Inc Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO

(609) 514-4744 Brian Kennedy (media)

(212) 691-8087

SOURCE Derma Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Engineers harness cell phone technology for use in medical imaging
2. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
3. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
4. Holly Smith Joins Profect as Director of Clinical Imaging Services
5. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
6. New Robotic Imaging Technology Holds Promise of Improved Cancer Care
7. First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference
8. BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations
9. Genetic pathway critical to disease, aging found
10. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
11. Diagnostic Imaging - Acquisitions - OTCBB: DIIG
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):